Indication · Neurology & Neurosurgery
Alzheimer's disease and dementia
Last checked: Nov 20, 2026Source: FDA, ClinicalTrials.gov
Devices
12
Cleared or approved since 2000
PMA and De Novo
4
Higher-risk or first-of-kind devices
Breakthrough devices
5
Authorized through June 30, 2026
Recruiting device trials
180
917 device trials in all
Breakthrough-designated devices
- Elecsys Phospho-Tau (217P) PlasmaRoche Diagnostics · 2026
4 more devices with a free account
Devices
12 devices. PMA and De Novo devices first, then devices with the most FDA decisions. Each opens a full summary.
- APO-Easy Genotyping kit
Firalis SA · De Novo · Neurologic Disease Risk Assessment Molecular Test · newest 2025
11 more devices with a free account
Device trials
Device studies on ClinicalTrials.gov for this condition, any status, newest update first.
IRCCS Centro San Giovanni di Dio FatebenefratelliAcademic, hospital or other
NCT05730023 · 70 participants · Start Feb 1, 2023 · Primary completion Jan 13, 2026
Device: Active tDCS; Placebo tDCS · For: Primary Progressive Aphasia
Sites: Brescia, Italy; Pavia, Italy; Milan, Italy · 4 sites in all
916 more trials with a free account
Device types
FDA product codes mapped to this indication. The mapping was made with AI help and may include a few loose fits.
Research
- Device studies on Alzheimer disease across PubMed, Europe PMC and OpenAlex
- PubMed ↗
- Google Scholar ↗
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.